CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 36 enrolled
Drug / intervention
Tiotropium +1 moredrug
Likely dose
Tiotropium 18 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00578968
NCT00578968Phase 4Completed
CompareCT.gov

Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation

Mayo Clinic·interventional·Posted Dec 21, 2007·Updated Jun 26, 2012

In Brief

A Phase 4 clinical trial evaluating Tiotropium and Placebo for Chronic Obstructive Pulmonary Disease and COPD. Completed, enrolled 36 participants across 1 site.

Detailed Summary

This study is being done to examine the influence of Tiotropium (good or bad) on heart function at rest and during exercise in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease, COPD
CountriesUnited States
CollaboratorsBoehringer Ingelheim, Pfizer

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 21, 2007
Enrollment StartOct 1, 2006
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.5 years ago

Interventions

Tiotropiumdrug

Participants received once daily Spiriva capsules for oral inhalation: 18 mcg tiotropium powder, for use with HandiHaler device.

Placebodrug

Participants randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose, using the HandiHaler device.